Item 8.01 Other Events

On February 2, 2009, Acorda Therapeutics, Inc. (the "Registrant") issued a press release announcing the submission of a New Drug Application to the U.S. Food and Drug Administration on January 30, 2009 for Fampridine-SR. The Company also announced that it has discussed Fampridine-SR with regulatory authorities in Europe and believes that the current data are sufficient to file a centralized Marketing Authorization Application (MAA) with the European Medicines Agency, and that it plans to file the MAA when it has determined the commercialization pathway that maximizes the value of Fampridine-SR outside the U.S. The Registrant's press release is filed as Exhibit 99.1 hereto and incorporated by reference into this item 8.01.